(CheckMate 743) :,,,3

Paul Baas1, Arnaud Scherpereel2, Anna K Nowak3

  • 1The Netherlands Cancer Institute and Leiden University Medical Center, Amsterdam, Netherlands.

Lancet (London, England)
|January 24, 2021
PubMed
まとめ

ニボルマブとイピリムマブは,化学療法と比較して,悪性多頭筋内皮腫 (MPM) の患者の全生存期間を有意に改善しました. この免疫療法の組み合わせは,切除不能のMPMに対する新しい効果的な治療法を提供します.

関連する概念動画

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...